Alibaba
BABA
Apple
AAPL
Intel
INTC
4
Netflix
NFLX
5
Tesla
TSLA
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 1.5400
- +0.0200+1.32%
Close Mar 27 16:00 ET
9.39MMarket Cap-0.59P/E (TTM)
1.5400High1.5100Low52.02KVolume1.5100Open1.5200Pre Close78.87KTurnover0.85%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High3.78P/B9.39MFloat Cap1.290052wk Low--Dividend TTM6.10MShs Float1419.0000Historical High--Div YieldTTM1.97%Amplitude1.2900Historical Low1.5160Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Can-Fite BioPharma Stock Forum
Major Breakthrough: New Oral Psoriasis Drug Enters Final Testing Phase with Dual Regulatory Backing
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Monday, 24th March at 9:00 am
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs
Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflam...
Ramat Gan, Israel, March 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it...
Can-Fite's veterinary partnership with Vetbiolix represents a strategic expansion into the $3.8 billion companion animal arthritis market, with Piclidenoson now advancing to an advanced clinical study following successful initial results. The move leverages their existing A3 Adenosine Receptor technology platform into veterinary medicine, where development timelines and approval processes are typically accelerated compared to human therapeutics.
The...
Can-Fite's Breakthrough: New Pet Arthritis Drug Targets Massive $3.8B Market Opportunity
Breakthrough: Can-Fite's Piclidenoson Could Be First Drug for Fatal Genetic Disease
3 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients
Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological ...
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Wednesday, 19th March at 9:00 am
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients
Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammat...
No comment yet